A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Neuro-Oncology

Volumn 18, Issue 8, 2016, Pages 1146-1156

  Brandes, Alba A ^a   Carpentier, Antoine F ^b   Kesari, Santosh ^c   Sepulveda Sanchez, Juan M ^d   Wheeler, Helen R ^e   Chinot, Olivier ^f   Cher, Lawrence ^g   Steinbach, Joachim P ^h   Capper, David ⁱ   Specenier, Pol ^j   Rodon, Jordi ^k   Cleverly, Ann ^l   Smith, Claire ^l   Gueorguieva, Ivelina ^l   Miles, Colin ^l   Guba, Susan C ^l   Desaiah, Durisala ^l   Lahn, Michael M ^l   Wick, Wolfgang ^m  

^a MAGGIORE HOSPITAL   (Italy)

^b AVICENNE HOSPITAL   (France)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f CHU Hôspital de la Timone   (France)

^g AUSTIN HOSPITAL   (Australia)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^j ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l ELI LILLY AND COMPANY   (United States)

^m UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

Antitumor activity; Bayesian design; Galunisertib monohydrate (LY2157299); Pharmacokinetics; Phase II randomized study; Safety

Indexed keywords

GALUNISERTIB; LOMUSTINE; PLACEBO; ALKYLATING AGENT; LY-2157299; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOLUME OF DISTRIBUTION; VOMITING; BRAIN TUMOR; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; PROCEDURES;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; LOMUSTINE; MALE; MIDDLE AGED; PYRAZOLES; QUINOLINES; TREATMENT OUTCOME;

EID: 84982131467     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now009     Document Type: Article

References (43)

1. Stupp R, Pavlidis N, Jelic S, ESMO Guidelines Task Force. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol. 2005;16(Suppl 1): i64-i65
2. Agnihotri S, Burrell KE,Wolf A, et al. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp. 2013;61(1):25-41
3. Golestaneh N, Mishra B. TGF-b, neuronal stem cells and glioblastoma. Oncogene. 2005;24(37):5722-5730
4. Schneider T, Sailer M, Ansorge S, Firsching R, Reinhold D. Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol. 2006; 79(1):61-65
5. Bruna A, Darken RS, Rojo F, et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007;11(2):147-160
6. Penuelas S, Anido J, Prieto-Sanchez RM, et al. TGF-b Increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15(4):315-327
7. Tritschler I, Gramatzki D, Capper DD, et al. Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells. Int J Cancer. 2009;125(3):530-540
8. Wild-Bode C, Weller M, Wick W. Molecular determinants of glioma cell migration and invasion. J Neurosurg. 2001;94(6):978-984
9. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66(6):3294-3302
10. Uhl M, Aulwurm S, Wischhusen J, et al. SD-208, a novel transforming growth factor b receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004;64(21):7954-7961
11. Tran TT, Uhl M, Ma JY, et al. Inhibiting TGF-b signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol. 2007;9(3):259-270
12. Anido J, Saez-Borderías A, Gonzalez-Junca A, et al. TGFß receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell. 2010;18(6): 655-668
13. Rodon J, Carducci MA, Sepulveda-Sanchez JM, et al. First-in-human dose study of the novel transforming growth factor-b receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res. 2015; 21(3):553-560
14. Parsons S, Sawyer S, Yan L, et al. The combination of the small molecule TGFbR1 inhibitor LY2157299 monohydrate with CCNU substantially blocks SMAD phosphorylation and significantly suppresses human glioblastoma xenograft growth. Paper presented at: AACR-NCI-EORTC 2011; AACR. Mol Cancer Ther. 2011;10(Suppl 11): C201
15. Stupp R, Brada M, van den Bent MJ, et al. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii93-iii101
16. Brandes AA, Tosoni A, Spagnolli F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol. 2008;10(3):361-367
17. Gueorguieva I, Cleverly AL, Stauber A, et al. Defining a therapeutic window for the novel TGF-b inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br J Clin Pharmacol. 2014;77(5):796-807
18. Han B, Enas NH, McEntegart D. Randomization by minimization for unbalanced treatment allocation. Stat Med. 2009;28(27): 3329-3346
19. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7): 1168-1174
20. Batchelor TT, Mulholland P, Neyns B, et al. The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a Phase III randomized study. Neuro Oncol. 2010;12:iv69-iv78
21. Wick W, Brandes AA, Gorlia T, et al. Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC 26101 Trial. Neuro Oncol. 2015;17(suppl 5):v1
22. Preusser M, Capper D, Hartmann C. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol. 2011;30(5): 217-230
23. Rodon J, Carducci M, Sepulveda-Sanchez JM, et al. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-b receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs. 2015;33(2):357-370
24. Baron U, Floess S, Wieczorek G, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional Tcells. Eur J Immunol. 2007;37(9):2378-2389
25. Tahara H, Sato M, Thurin M, et al. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med. 2009;7:45
26. Armstrong TS, Mendoza T, Gning I, et al. Validation of the M. D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol. 2006;80(1):27-35
27. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12:43-55
28. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol. 2006;24(8):1305-1309
29. Reitan RM. Trail Making Test. Manual for Administration and Scoring. South Tucson, AZ: Reitan Neuropsychology Laboratory; 1992
30. Ruff RM, Light RH, Parker SB. Benton controlled oral word association test: reliability and updated norms. Arch Clin Neuropsychol. 1996;11(4):329-338
31. Wefel J, Cloughesy T, Zazzali JL, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011;13(6):660-668
32. Giannelli G, Faivre S, Santoro A. Evaluation of LY2157299 monohydrate, a TGF-b receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma: Phase 2 study results of safety, efficacy and PK/PD. Presented at: International Liver Congress 2014; April 9-13, 2014; London, England. Abstract A-627-0008-03078
33. Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw. 2011;9(4):403-407
34. Herbertz S, Sawyer JS, Stauber AJ, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther. 2015;9:4479-4499
35. Baumann F, Leukel P, Doerfelt A, et al. Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neurol Oncol. 2009;11(4):368-380
36. Kanner AA, Marchi N, Vincent Fazio V, et al. Serum S100b:A noninvasive marker of blood-brain barrier function and brain lesions. Cancer. 2003;97:2806-2813
37. Bambury RM, Teo MY, Power DG, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol. 2013;114(1):149-154
38. Zhou M, Bracci PM, McCoy LS, et al. Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4T cell lymphopenia and survival time. Int J Cancer. 2015;137(4): 826-836
39. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006; 8(3):261-279
40. Mantovani A, Gray PA, Van Damme J, Sozzani S. Macrophagederived chemokine (MDC). J Leukoc Biol. 2000;68(3):400-404
41. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005;76(2):77-98
42. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003;100(9): 5336-5341
43. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580-6587